Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 601 to 610 of 1443 total matches.
Ryanodex - A New Dantrolene Formulation for Malignant Hyperthermia
The Medical Letter on Drugs and Therapeutics • Jul 06, 2015 (Issue 1472)
. ©2015. www.fdbhealth.com/policies/drug-pricing-policy.
101
The Medical Letter ® Vol. 57 (1472) July 6 ...
The FDA has approved a new IV formulation of
dantrolene (Ryanodex – Eagle) for prevention and
treatment of malignant hyperthermia in adults and
children. The new formulation requires fewer vials,
less fluid volume, and less time for preparation and
administration than other available IV dantrolene
products (Dantrium, Revonto).
Eliglustat (Cerdelga) - An Oral Drug for Gaucher Disease (online only)
The Medical Letter on Drugs and Therapeutics • Jul 06, 2015 (Issue 1472)
poor metabolizers
e101
The Medical Letter ® Vol. 57 (1472) July 6, 2015
QRS intervals, concurrent ...
The FDA has approved eliglustat (Cerdelga –
Genzyme), an oral glucosylceramide synthase inhibitor,
for treatment of adults with type 1 Gaucher disease.
Eliglustat is metabolized primarily by CYP2D6. Because
patients who are CYP2D6 ultra-rapid metabolizers may
not achieve therapeutic concentrations and a specific
dosage cannot be recommended for indeterminate
metabolizers, the FDA has approved the drug only
for patients who are extensive, intermediate, or poor
metabolizers of CYP2D6.
Liraglutide (Saxenda) for Weight Loss
The Medical Letter on Drugs and Therapeutics • Jun 22, 2015 (Issue 1471)
during pregnancy because weight loss is not
90
The Medical Letter ® Vol. 57 (1471) June 22, 2015 ...
The injectable glucagon-like peptide-1 (GLP-1)
receptor agonist liraglutide, previously approved by the
FDA for treatment of type 2 diabetes as Victoza, has
now also been approved at a higher dose as Saxenda
(Novo Nordisk) for chronic weight management
in adults with a BMI ≥30, or a BMI ≥27 with a
weight-related comorbidity such as hypertension,
dyslipidemia, or diabetes.
Which PPI?
The Medical Letter on Drugs and Therapeutics • Jun 22, 2015 (Issue 1471)
on soft food or liquid and taken within 15 minutes.
92
The Medical Letter ® Vol. 57 (1471) June 22, 2015 ...
An article published in the New York Times on May 1,
2015 listed the 10 drugs on which Medicare Part D
spent the most in 2013. The most costly ($2.53
billion) was the proton pump inhibitor (PPI) Nexium
(esomeprazole magnesium), which has recently become
available generically.
Droxidopa (Northera) for Neurogenic Orthostatic Hypotension
The Medical Letter on Drugs and Therapeutics • Jun 22, 2015 (Issue 1471)
been titrated to an optimized dose of
93
The Medical Letter ® Vol. 57 (1471) June 22, 2015
of 100 mg three ...
The FDA has approved droxidopa (Northera –
Lundbeck) for oral treatment of adults with symptomatic
neurogenic orthostatic hypotension (NOH) caused
by primary autonomic failure (Parkinson's disease,
multiple system atrophy, or pure autonomic failure),
dopamine beta-hydroxylase deficiency, or nondiabetic
autonomic neuropathy. This is the first approval for
droxidopa in the US. It has been available in Japan for
use in NOH since 1989.
Bellafill for Acne Scars
The Medical Letter on Drugs and Therapeutics • Jun 22, 2015 (Issue 1471)
from unintentional injection of dermal fillers
into facial blood vessels.
94
The Medical Letter ® Vol. 57 (1471 ...
Bellafill (Suneva), a dermal filler approved earlier for
correction of nasolabial folds, has now also been
approved by the FDA for correction of moderate to
severe, atrophic, distensible facial acne scars on the
cheek in adults ≥21 years old. It is the only dermal filler
approved in the US for correction of facial acne scars.
Nivolumab (Opdivo) for Metastatic Melanoma and Metastatic NSCLC
The Medical Letter on Drugs and Therapeutics • Jun 08, 2015 (Issue 1470)
in 142 patients
86
The Medical Letter ® Vol. 57 (1470) June 8, 2015
Table 1. Some Drugs for Metastatic ...
The FDA has approved nivolumab (Opdivo – BMS),
an IV programmed death receptor-1 (PD-1) blocking
antibody, for treatment of unresectable or metastatic
melanoma that has progressed following treatment
with ipilimumab (and a BRAF inhibitor in patients who
are BRAF V600 mutation positive) and for treatment
of metastatic squamous non-small cell lung cancer
(NSCLC) that has progressed on or after platinum-based
chemotherapy. It is the second PD-1 inhibitor to
be marketed in the US after pembrolizumab (Keytruda),
and the first to be approved for treatment of NSCLC.
Recombinant Human Parathyroid Hormone (Natpara)
The Medical Letter on Drugs and Therapeutics • Jun 08, 2015 (Issue 1470)
The Medical Letter ® Vol. 57 (1470) June 8, 2015
Natpara powder is supplied in a glass cartridge and
must ...
The FDA has approved a subcutaneously injected
formulation of recombinant human parathyroid
hormone (Natpara – NPS) as an adjunct to calcium
and vitamin D to control hypocalcemia in adults
with hypoparathyroidism. Natpara is an 84-amino
acid single-chain polypeptide identical to native
parathyroid hormone. It is the first parathyroid hormone
formulation to be approved for this indication.
Ceftazidime/Avibactam (Avycaz) - A New Intravenous Antibiotic
The Medical Letter on Drugs and Therapeutics • May 25, 2015 (Issue 1469)
, meropenem, or doripenem)
could be used.3,4
80
The Medical Letter ® Vol. 57 (1469) May 25, 2015 ...
The FDA has approved ceftazidime/avibactam
(Avycaz – Actavis) for IV treatment of complicated
urinary tract and intra-abdominal infections in adults
who have limited or no other treatment options.
Ceftolozane/tazobactam (Zerbaxa – Cubist), another
cephalosporin/beta-lactamase inhibitor combination,
was approved in 2014.
Fluticasone Furoate (Arnuity Ellipta) for Asthma
The Medical Letter on Drugs and Therapeutics • May 25, 2015 (Issue 1469)
to fluticasone propionate in improving
trough FEV1 from baseline.
77
The Medical Letter ® Vol. 57 (1469 ...
The FDA has approved Arnuity Ellipta (GSK), a single-agent
inhaler containing the corticosteroid fluticasone
furoate, for once-daily maintenance treatment of
asthma in patients ≥12 years old. Fluticasone furoate
is also available in combination with the long-acting
beta2-agonist vilanterol as Breo Ellipta for treatment
of asthma and COPD.